



Physician Safety and Stent Savings with Robotic-Assisted PCI to be Presented at CRT 2015

Corindus CorPath® System user to present study findings

Waltham, MA – February 18, 2015 – Corindus Vascular Robotics, Inc. [OTCQB: CVRS], a leading developer of precision vascular robotics, today announced that a study submitted by a physician user of the company's CorPath System will be presented at the Cardiovascular Research Technologies (CRT) conference on Monday, February 23, 2015 in Washington, D.C. The study, led by Paul T. Campbell, M.D., Carolinas Medical Center Northeast, explores the stent savings made possible when robotic PCI is leveraged for the measurement of anatomy in place of the conventional, manual methods of measurement.

"Improving accuracy in stent selection through robotic-assisted measurement can help physicians avoid Longitudinal Geographic Miss and potentially improve clinical outcomes for patients," said Campbell. "It also reduces the need for additional stents, delivering procedural cost-savings to hospitals. The combination of radiation safety and precision available through the use of robotics in interventional cardiology provides advancements that can significantly benefit cath lab physicians."

The issue of inaccurate measurement of lesions was recently the highlight of an article published in *Catheterization and Cardiovascular Interventions*, which evaluated the accuracy of interventional cardiologists utilizing visual estimation to determine lesion length. "*Interoperator and intraoperator (in)accuracy of stent selection based on visual estimation*," of which Campbell was also an author, found that visual estimation of lesion length for PCI had a high degree of variability – potentially contributing to inappropriate stent selection and increasing patients' risk of restenosis. The study concluded that patient outcomes may benefit from improvements in lesion length measurement and stent selection.

"The CorPath System was designed to empower physicians in the cath lab– starting with their personal health and safety through protection from harmful radiation exposure, and by enhancing their clinical capability by utilizing robotic precision," said David Handler, president and CEO, Corindus Vascular Robotics. "Sub-millimeter measurement capability and enhanced visualization, combined with CorPath's radiation-shielding, helps physicians treat their patients' and protect their own well-being."

The CorPath System is the first FDA-cleared medical device to bring robotic-assistance to coronary angioplasty procedures. It enables physicians to perform procedures while seated in a lead-lined interventional cockpit protected from radiation exposure. CorPath allows cardiologists to advance stents and guidewires millimeter-by-millimeter using digital controls.

To learn more about the CorPath System, visit booth #102 at CRT2015. For additional information, visit www.corindus.com.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's FDA-cleared CorPath 200 System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI

procedures to help physicians potentially provide better clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus' control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus' financial results is included from time to time in the "Forward Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Corindus' periodic and current filings with the SEC, as well as those discussed under the "Risk Factors" and "Forward Looking Statements" section of Corindus' Prospectus, dated January 16, 2015, filed with the SEC and available on Corindus' website at <http://www.corindus.com/about-corindus/investor-relations>. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.

###

Media Contacts:

Corindus Vascular Robotics

Brett Prince

(508) 653-3335 ext. 231

brett.prince@corindus.com

Sourav Das

203-504-8230 ext. 131

corindus@knbpr.com